Atezolizumab Plus Bevacizumab Combined with or without Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study.

IF 4.2 3区 医学 Q2 ONCOLOGY
Journal of Hepatocellular Carcinoma Pub Date : 2025-05-15 eCollection Date: 2025-01-01 DOI:10.2147/JHC.S515453
Jing Li, Yaowei Bai, Fu Xiong, Xiaocui Liu, Junwen Hu, Guilin Zhang, Jiayun Liu, Suyue Wu, Chuansheng Zheng, Xuefeng Kan
{"title":"Atezolizumab Plus Bevacizumab Combined with or without Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study.","authors":"Jing Li, Yaowei Bai, Fu Xiong, Xiaocui Liu, Junwen Hu, Guilin Zhang, Jiayun Liu, Suyue Wu, Chuansheng Zheng, Xuefeng Kan","doi":"10.2147/JHC.S515453","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to compare the efficacy and safety of atezolizumab plus bevacizumab (T+A) in combination with transarterial chemoembolization (TACE) (T+A+TACE) and T+A for patients with advanced hepatocellular carcinoma (HCC).</p><p><strong>Patients and methods: </strong>From December 2020 to August 2024, 83 patients with advanced HCC who received T+A+TACE treatment or T+A treatment in our hospital were included, and these patients were categorized into TACE+T+A group (n=52) and T+A group (n=31). The clinical outcomes between the two groups were analyzed and compared, and the prognostic factors that affected the efficacy were analyzed.</p><p><strong>Results: </strong>The median overall survival (OS) and median progression-free survival (PFS) in the T+A+TACE group were significantly longer than those of in the T+A group (OS: 22.8 vs 16.9 months, <i>P</i> = 0.015; PFS: 7.1 vs 4.9 months, <i>P</i> = 0.006). A significantly higher objective response rate (ORR) and disease control rate (DCR) that are based on the modified RECIST were achieved in the T+A+TACE group than those of in the T+A group (ORR: 51.9% vs 6.5%, <i>P</i> < 0.001; DCR: 88.5% vs 54.8%, <i>P</i> < 0.001). No significant differences in adverse events (AEs) were observed between the two groups (<i>P</i> > 0.05). The T+A+TACE treatment was identified as a protective factor for OS and PFS.</p><p><strong>Conclusion: </strong>TACE further improved the efficacy of T+A treatment for patients with advanced HCC, and it did not increase the incidence of AEs. T+A+TACE treatment is a promising treatment option for patients with advanced HCC.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"973-984"},"PeriodicalIF":4.2000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090845/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S515453","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This study aimed to compare the efficacy and safety of atezolizumab plus bevacizumab (T+A) in combination with transarterial chemoembolization (TACE) (T+A+TACE) and T+A for patients with advanced hepatocellular carcinoma (HCC).

Patients and methods: From December 2020 to August 2024, 83 patients with advanced HCC who received T+A+TACE treatment or T+A treatment in our hospital were included, and these patients were categorized into TACE+T+A group (n=52) and T+A group (n=31). The clinical outcomes between the two groups were analyzed and compared, and the prognostic factors that affected the efficacy were analyzed.

Results: The median overall survival (OS) and median progression-free survival (PFS) in the T+A+TACE group were significantly longer than those of in the T+A group (OS: 22.8 vs 16.9 months, P = 0.015; PFS: 7.1 vs 4.9 months, P = 0.006). A significantly higher objective response rate (ORR) and disease control rate (DCR) that are based on the modified RECIST were achieved in the T+A+TACE group than those of in the T+A group (ORR: 51.9% vs 6.5%, P < 0.001; DCR: 88.5% vs 54.8%, P < 0.001). No significant differences in adverse events (AEs) were observed between the two groups (P > 0.05). The T+A+TACE treatment was identified as a protective factor for OS and PFS.

Conclusion: TACE further improved the efficacy of T+A treatment for patients with advanced HCC, and it did not increase the incidence of AEs. T+A+TACE treatment is a promising treatment option for patients with advanced HCC.

Atezolizumab +贝伐单抗联合或不联合经动脉化疗栓塞治疗晚期肝细胞癌:单中心回顾性研究
目的:本研究旨在比较atezolizumab联合贝伐单抗(T+A)联合经动脉化疗栓塞(TACE) (T+A+TACE)和T+A治疗晚期肝细胞癌(HCC)患者的疗效和安全性。患者与方法:纳入2020年12月至2024年8月在我院接受T+A+TACE治疗或T+A治疗的晚期HCC患者83例,分为TACE+T+A组(n=52)和T+A组(n=31)。分析比较两组患者的临床结局,并分析影响疗效的预后因素。结果:T+A+TACE组的中位总生存期(OS)和中位无进展生存期(PFS)明显长于T+A组(OS: 22.8个月vs 16.9个月,P = 0.015;PFS: 7.1 vs 4.9个月,P = 0.006)。基于改良RECIST的客观缓解率(ORR)和疾病控制率(DCR), T+A+TACE组显著高于T+A组(ORR: 51.9% vs 6.5%, P < 0.001;DCR: 88.5% vs 54.8%, P < 0.001)。两组不良事件发生率比较,差异无统计学意义(P < 0.05)。T+A+TACE治疗被确定为OS和PFS的保护因素。结论:TACE进一步提高了T+A治疗晚期HCC患者的疗效,且未增加ae的发生率。T+A+TACE治疗是晚期HCC患者的一种有希望的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
2.40%
发文量
108
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信